Post Autologous Transplantation Consolidation of Multiple Myeloma with Idiotype-Pulsed Antigen Presenting (Dendritic) Cells (APC8020) Is Associated with Prolonged Survival

被引：0
|
作者：
Lacy, Martha Q. [1 ]
Mandrekar, Sumithra [1 ]
Kabat, Brian [1 ]
Dispenzieri, Angela [1 ]
Hayman, Suzanne [1 ]
Kumar, Shaji [1 ]
Buadi, Francis [1 ]
Dingli, David [1 ]
Litzow, Mark [1 ]
Wettstein, Peter [1 ]
Rajkumar, S. Vincent [1 ]
Gastineau, Dennis [1 ]
Gertz, Morie A. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：613 / 613
页数：1
相关论文
共 25 条
  • [1] Post autologous transplantation consolidation of multiple myeloma with idiotype-pulsed antigen presenting (dendritic) cells (APC8020) is associated with a trend to longer time to progression (TTP).
    Lacy, MQ
    Geyer, S
    Wettstein, P
    Gertz, MA
    Gastineau, DA
    Greipp, PR
    Fonseca, R
    Dispenzieri, A
    Lust, JA
    Witzig, TE
    Rajkumar, SV
    Zeldenrust, S
    Maas, M
    Iturria, N
    Weiden, P
    Kyle, RA
    [J]. BLOOD, 2002, 100 (11) : 433A - 433A
  • [2] Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival
    Lacy, Martha Q.
    Mandrekar, Sumithra
    Dispenzieri, Angela
    Hayman, Suzanne
    Kumar, Shaji
    Buadi, Francis
    Dingli, David
    Litzow, Mark
    Wettstein, Peter
    Padley, Douglas
    Kabat, Brian
    Gastineau, Dennis
    Rajkumar, S. Vincent
    Gertz, Morie A.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (12) : 799 - 802
  • [3] Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival (vol 84, pg 799, 2009)
    Lacy, M. Q.
    Mandrekar, S.
    Dispenzieri, A.
    Hayman, S.
    Kumar, S.
    Buadi, F.
    Dingli, D.
    Litzow, M.
    Wettstein, P.
    Padley, D.
    Kabat, B.
    Gastineau, D.
    Rajkumar, S., V
    Gertz, M. A.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (04) : 309 - 309
  • [4] Phase I/II trial of immunotherapy with idiotype-loaded autologous dendritic cells (APC8020) for refractory multiple myeloma.
    MacKenzie, M
    Strang, G
    Peshwa, M
    Sopapan, J
    Valone, F
    [J]. BLOOD, 1998, 92 (10) : 108A - 108A
  • [5] Efficacy of idiotype-pulsed autologous dendritic cells for treatment of advanced refractory multiple myeloma.
    MacKenzie, M
    Peshwa, MV
    Wun, T
    Strang, G
    Wolf, J
    Gutheil, J
    Mason, J
    Caggiano, V
    Valone, FH
    [J]. BLOOD, 1999, 94 (10) : 122A - 122A
  • [6] Immunotherapy of advanced refractory multiple myeloma with idiotype-pulsed dendritic cells (Mylovenge).
    MacKenzie, M
    Peshwa, MV
    Wun, T
    Wolf, J
    Mason, J
    Caggiano, V
    Redfern, C
    Strang, G
    Valone, F
    [J]. BLOOD, 2000, 96 (11) : 166A - 166A
  • [7] Induction of antitumor immunity by idiotype-pulsed dendritic cells against established multiple myeloma
    Zeis, M
    Uharek, L
    Glass, B
    Krönke, M
    Steinmann, J
    Schmitz, N
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 286 - 287
  • [8] Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects
    Titzer, S
    Christensen, O
    Manzke, O
    Tesch, H
    Wolf, J
    Emmerich, B
    Carsten, C
    Diehl, V
    Bohlen, H
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2000, 108 (04) : 805 - 816
  • [9] Induction of Cellular Immune Responses in Patients With Stage-I Multiple Myeloma After Vaccination With Autologous Idiotype-pulsed Dendritic Cells
    Roellig, Christoph
    Schmidt, Christian
    Bornhaeuser, Martin
    Ehninger, Gerhard
    Schmitz, Marc
    Auffermann-Gretzinger, Susanne
    [J]. JOURNAL OF IMMUNOTHERAPY, 2011, 34 (01) : 100 - 106
  • [10] Natural cytotoxicity to autologous antigen-pulsed dendritic cells in multiple myeloma
    Zheng, CY
    Ostad, M
    Andersson, M
    Celsing, F
    Holm, G
    Sundblad, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (03) : 778 - 785
123